DOCSLIB.ORG

USAMRIID Overview

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
USAMRIID Overview UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES USAMRIID Overview for the Frederick County Containment Laboratory Community Advisory Committee Colonel John P. Skvorak, DVM, Ph.D. Commander www.usamriid.army.mil USAMRIID History First US biowarfare facility was started in April 1943 at Camp Detrick in quickly built facilities and in Air National Guard buildings that were adapted for use. The US Army Medical Unit (USAMU) was created in 1956 to develop the means to diagnose, treat, and prevent diseases caused by biological warfare agents. President Nixon ended the Biowarfare R&D Program in 1969 but allowed continued development of medical countermeasures. USAMU was renamed USAMRIID, 27 January 1969. Chain of Command U.S. Army Medical Command LTG Eric Schoomaker US Army Surgeon General U.S. Army Medical Research and Materiel Command MG James Gilman USAMRIID COL John P. Skvorak USAMRIID Mission and Vision We conduct research on current and emerging biodefense threats, resulting in medical solutions to protect the Warfighter. %HWKH1DWLRQ¶VSUH-eminent research laboratory for medical biological defense, providing innovative solutions to protect the Warfighter. First Things First What we do: Who we are: Develop and test vaccines, About 850 civilians and military drugs and diagnostic tests to personnel, with jobs ranging protect against known from administration to research biological threats Most of us live in Frederick Publish and present our County research findings :KDWZHGRQ¶WGR Educate and train medical Conduct classified research personnel Conduct offensive research Provide expert consultation and assistance on emerging Develop new biological threats diseases and other issues DoD Chem/Bio Defense Program Organization Convergence of Military & Civilian Biodefense Requirements Post-9/11 PA RT N E RSH IPS Biosecurity Biosecurity Biosecurity Requirements Requirements Requirements to the by the Military to the Military and the Nation Nation DoD ± US Department of Defense D H HS ± US Department of Health and Human Services Biological Agents in USAMRIID Research Category A Category B Bacillus anthracis (Anthrax) Coxiella burnetti (Q fever) Clostridium botulinum (Botulism) Burkholderia pseudomallei Burkholderia mallei (Glanders) Yersinia pestis (Plague) Brucella species (Brucellosis) Variola major (Smallpox*) & other Ricin toxin pox viruses Staphylococcus enterotoxin B Francisella tularensis (Tularemia) VEE, WEE, EEE (Equine Lassa Fever Virus Encephalitis Viruses) South American Hemorrhagic Fever Viruses Category C Hantaviruses Crimean-Congo Hemorrhagic Fever Rift Valley Fever Virus Ebola Virus Yellow Fever Marburg Virus Influenza * Only at the CDC Lab in Atlanta 86$05,,'¶V&ULWLFDO&RUH&RPSHWHQFLHV Biocontainment Laboratories Bio Agents Animal Care and Use Potential Exposure Rate 20.0 17.4 15.0 10.0 9.1 9.5 6.6 6.4 5.0 4.6 rate/1000emp 0.0 FY 2000 FY 2001 FY 2002 FY 2003 FY 2004 FY 2005 Subject Matter Expertise Safety, Security, Surety Aerobiology 86$05,,'¶V8QLTXH)DFLOLWLHV Biosafety level (BSL)-4 -- 8,400 gsf (9,600 after renovation complete) 3 suites, 11 laboratory rooms BSL-3 -- 41,800 (gsf) 14 suites, 108 laboratory rooms BSL-2 -- 53,700 gsf 96 laboratory rooms Animal care facility 75 rooms in BSL-2,3,4 Center for Aerobiology 9 Class 3 biosafety cabinets (BSC) (7 BSL-3, 2 BSL-4) Field laboratory training center USAMRIID Science Program Overview Pretreatments 9 Vaccines for bacterial, toxin, and viral agents with the current focus on Burkholderia, ricin, and Filoviruses 9 Multi-agent vaccines Therapeutics for bacterial, toxin, and viral agents 9 Current focus on plague, Burkholderia, botulinum, and Filoviruses 9 Special interest in broad spectrum ± Focus on hemorrhagic fever viruses and intracellular bacterial pathogens ± Looking for common disease causing or host response pathways Diagnostic technologies 9 Current focus on assay development for existing platforms, assay standardization, evaluation of next generation diagnostic capabilities Animal Models 9 Safety 9 Evaluate efficacy of vaccines and therapies following infection Vaccine protects from disease Therapeutic enables recovery Best delivery method 9 Efficacy/mode of exposure to pathogen 86$05,,'¶V&XUUHQW2SHUDWLRQDO0RGHO Leverage From External Sources ~650 active agreements (selected examples) Product Candidates Antisense Oligos (ex. AVI Biopharma, Tekmira) Novel antimicrobials (ex.Novartis, Siga, Combinatorx) Vaccine candidates (ex.AlphaVax, NIAID VRC) USAMRIID Pathogenesis studies Technologies Diagnostic systems (ex. BioVeris, Idaho Technologies) Adaptation of technology to Antibodies (ex. VaxDesign, BioFactura, Abgenix) biodefense countermeasures Vaccine delivery devices (ex. Pfizer, Ichor, Inovio, B-D) Animal model development Vaccine vectors (ex. RML, Vical, Crucell) Evaluation of Adjuvants (ex. Pfizer, Novartis) countermeasure Concepts & Capabilities DNA vaccination siRNA Reverse genetics (ex. LANL, Columbia U., NMRC) Provide to Customers Host targets for viral assembly (ex. Prosetta) Bioinformatics (ex. JCVI, VBI, LANL, BHSAI) Product candidates Transgenic Mice (ex. Lexicon Genetics, Jackson Labs) Technical information We apply cutting-edge approaches to our problem sets! Major Partnerships/Collaborations Academia Industry Government/Military Arizona State University Inovio Biomedical Centers for Disease Control and Baylor College of Medicine Integrated Biotherapeutics Prevention (CDC) Duke University Abgenix, Inc. Integrated Nano-Technologies Central Intelligence Agency (CIA) Akonni Biosystems, Inc. Invitrogen Corporation Frederick Community College Defense Intelligence Agency (DIA) Akubio Limited/T.R.U.E. (Grant) Isis Pharmaceuticals, Inc. Dept. of Health & Human Services George Mason University Aldevron, LLC Kemp Biotechnologies, Inc. Federal Bureau of Investigation (FBI) Hood College Allergan, Inc. Large Scale Biology Corporation Food and Drug Administration James Madison University Alnylam Pharmaceuticals Lexicon Genetics, Inc. Lawrence Livermore NL Johns Hopkins University Alpha Gamma Technologies, LigoCyte Pharmaceuticals, Inc. Los Alamos National Lab (LANL) Inc. Mapp Biopharmaceutical, Inc. Johns Hopkins University School of Medicine National Biodefense Analysis and AlphaVax Human Vaccines, Maxygen, Inc. Countermeasures Center (NBACC) Johns Hopkins University School of Public Health Inc. Meso Scale Diagnostics, LLC National Cancer Institute (NCI) Mount Sinai School of Medicine AOAC, International Microbiotix, Inc. National Institute of Allergy and Ohio University AVI BioPharma Inc. MicroFluidic Systems Infectious Diseases (NIAID) Oklahoma Medical Research Program Becton, Dickinson & Company MIDI Inc. National Institute of Environmental BioFactura, Inc. Morphotek, Incorporated Purdue University Health Sciences (NIEHS/NIH) BioReliance Corporation NanoVec National Institutes of Health (NIH) Rutgers - The State University BioSante Pharmaceuticals National Food Research Institute Secret Service Stanford University BioVeris Corporation Northrop Grumman Systems U.S. Department of Agriculture Thomas Jefferson Medical School Callisto Pharmaceuticals, Inc. Nuvelo, Inc. U.S.Postal Service Trudeau Institute Cepheid, Inc. Oncovir, Inc. 18th MEDCOM Chimerix Inc./TRUE Ordway Research Institute Tufts University Armed Forces Institute of Pathology Chiron Corporation Orion Integrated Biosciences, Inc. Army Research Laboratory Tulane School of Public Health and Tropical Medicine CombiMatrix Corporation Point Therapeutics, Inc. JPEO-CBD/JPM-CBMS Tulane University Health Sciences Center CombinatoRx, Inc. PowderMed Ltd. USAMRMC Laboratories University of Alabama CreatV MicroTech, Inc. Protiva Biotherapeutics, Inc. USUHS University of Arkansas CUBRC and Prosetta Protiveris, Inc. 1st and 9th AML Corporation Pulmatrix, Inc. University of California at San Francisco Cyto Pulse Sciences, Inc. Qiagen University of California, Santa Barbara Diversa Corporation Quaestech, LLC International University of Georgia Research Foundation DOR BioPharma, Inc. Roche Diagnostics Corporation University of Maryland DynPortVaccine Company, LLC SIGA Technologies, Inc. CBR MOU University of Massachusetts Medical School EluSys Therapeutics, Inc. Southern Research Institute (SRI) Defence Science & Technology Functional Genetics Structural Bioinformatics, Inc. Laboratories University of Michigan GenPhar, Inc. The Institute for Genomic Research PowderMed Ltd. University of North Carolina - Chapel Hill Gilead Sciences, Inc. The McConnell Group Public Health Agency Canada University of Pennsylvania Goodwin Biotechnology, Inc. VaxDesign Corporation Robert Koch Institute University of Pittsburgh GTC Biotherapeutics, Inc. VaxGen, Inc. University College London University of Texas Medical Branch ID Biomedical Corporation Vical Incorporated University of Calgary IGEN International, Inc. Virion Systems, Inc. University of Freiburg University of Utah Imigene, Inc. VivoMetrics, Inc. University of Glasgow University of Virginia Innovative Biosensors, Inc. University of Marburg University of Wyoming Virginia Tech / Virginia Bioinformatics Institute Washington University USAMRIID Biodefense Products Tularemia Vaccine (IND) Venezuelan Equine Encephalitis (VEE) Vaccines (IND) Eastern Equine Encephalitis (EEE) Vaccine (IND) Western Equine Encephalitis (WEE) Vaccine (IND) Available Botulinum Pentavalent Toxoid Vaccine (IND) Smallpox Vaccine (cell culture derived vaccinia virus) For Botulinum Antitoxin (human & horse) Use Vaccinia Immune Globulin Ribavirin
Load more

Recommended publications
  • Tarpey TCCC AMEDDJ 2005-2
    April-June 2005 Perspective 1 MG George W. Weightman Managing the MC Through a Team Approach and the Balanced Scorecard 3 BG Eric B. Schoomaker The AMEDD Personnel Proponency Directorate/The Structure Models 9 R. Clare Layton AMEDD Continuum of Medical Education 12 COL John M. Powers, MC, USA The Medical Corps Assignment Process 16 COL Jonathan H. Jaffin, MC, USA, et al The Reduction of Unwarranted Clinical Practice Variation in the AMEDD 18 LTC William A. Rice, MC, USA Medical Management of Medical Holdover Patients 24 COL Michael A. Deaton, MC, USA Medical Ethics in Detainee/Enemy Prisoners of War Care 27 COL Gregg Anders, MC, USA The “Intentional” Officer 29 COL Chuck Callahan, MC, USA The Tactical Combat Casualty Care Transition Initiative 33 CAPT Frank K. Butler, Jr, MC, USN/COL John B. Holcomb, MC, USA Tactical Combat Casualty Care in Operation Iraqi Freedom 38 CPT Michael J. Tarpey, MC, USA Battlefield Tourniquets: Modern Combat Lifesavers 42 Thomas J. Walters, PhD, et al Laboratory Evaluation of the U.S. Army One-Handed Tourniquet 44 Joseph C. Wenke, PhD, et al Laboratory Evaluation of Battlefield Tourniquets in Human Volunteers 50 Thomas J. Walters, PhD, et al The Chitosan-Based Hemostatic Dressing: Experience in Current Combat Operations 58 LTC Ian Wedmore, MC, USA, et al Can We Provide Level III Damage Control Surgical Procedures at a Level II Facility? 62 LTC Lorne H. Blackbourne, MC, USA/COL John B. Holcomb, MC, USA GWOT: Assessment, Treatment, and Evacuation of Burn Trauma Casualties 66 LTC Evan M. Renz, MC, USA, et al Also in this issue…….
    [Show full text]
  • Invitrogen Lentiarray Human CRISPR Library, 96-Well Plate User Guide
    USER GUIDE Invitrogen™ LentiArray™ Human CRISPR Library, 96-well Plate Catalog Numbers A31931, A31932, A31933, A31934, A31935, A31936, A31937, A31938, A31939, A31940, A31941, A31942, A31943, A31944, A31945, A31946, A31947, A31948, and A31949 Doc. Part No. 100044720 Pub. No. MAN0016075 Rev. B WARNING! Read the Safety Data Sheets (SDSs) and follow the handling instructions. Wear appropriate protective eyewear, clothing, and gloves. Safety Data Sheets (SDSs) are available from thermofisher.com/support. Product description Invitrogen™ LentiArray™ Human CRISPR libraries consist of pre-defined collection of gene families for functional genomics screening in an arrayed format. Each library targets a subset of human genes with up to 4 sequence-verified distinct lentiviral gRNA constructs per gene, pooled in a single well in a 96-well format. The gRNAs are based on the latest research on gRNA design. The gRNAs included in the LentiArray™ libraries are designed to knockout all known isoforms of the target genes and are selected for maximum knockout efficiency without sacrificing specificity. Characteristic Description Product Invitrogen™ LentiArray™ Human CRISPR Lentivirus Library (see Table 1, for details) Amount 4 aliquots of 50 µL/well per gene target (200 µL total per gene target) Viral titer • Libraries are delivered with a range of average titer between 2×107–2×108 TU/mL by puromycin antibiotic selection. • We recommend using 1×108 TU/mL for starting MOI calculations, see “MOI determination for screens“ on page 2 for additional guidance. Lentiviral map • gRNA expression is driven by a U6 promoter. • Includes puromycin resistance gene to allow selection of transduced cells. Plate layout • Refer to the associated PDF file for the plate map of the specific LentiArray™ Human CRISPR library and to the associated Excel files for gRNA target information.
    [Show full text]
  • RNA Isolation and Purification for Every Sample, RNA Type, and Application Isolate and Purify RNA with Confidence
    RNA isolation and purification For every sample, RNA type, and application Isolate and purify RNA with confidence RNA isolation is a crucial step in your quest to understand gene expression levels. With all the solutions that Thermo Fisher Scientific has to offer, you can be confident that you’re getting started on the right foot. Go ahead and push the limits of your research. We’ll be there to support you with robust RNA purification kits, trusted RNA tools, and experienced technical support, all backed by nearly 30 years of leadership and innovation in RNA technologies. • Isolate from any sample type, for any application • Obtain high-purity, intact RNA • Achieve high yields, even from small sample quantities Contents Methods of RNA isolation 4 RNA and sample types 5 RNA applications 6 Organic RNA extraction 8 Spin column RNA extraction 10 Lysate-based RNA extraction 11 Automated RNA purification 12 Transcriptome purification 14 mRNA purification 15 MicroRNA and small RNA purification 16 Viral RNA purification 18 RNA from FFPE samples 20 RNA isolation technology guide 22 Avoiding RNA degradation 26 Tips for handling RNA 27 RNA quantitation 28 Gene expression solutions 30 Gene expression research considerations 31 Superior cDNA synthesis for any application 32 Complete kit with flexible priming options 33 Which instrument fits your needs? 34 Which thermal cycler or PCR instrument fits your needs? 35 RNA technical resources 36 Services and support 37 Ordering information 38 Methods of RNA isolation For every application, sample, and RNA type For over three decades, our scientists have developed and professional support. Our RNA isolation products innovative and robust RNA isolation products designed include organic reagents, columns, sample lysate, and to make your job as a scientist easier.
    [Show full text]
  • These Highlights Do Not Include All the Information Needed to Use ANTHIM Safely and Effectively. See Full Prescribing Information for ANTHIM
    ANTHIM - obiltoxaximab solution Elusys Therapeutics, Inc. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ANTHIM safely and effectively. See full prescribing information for ANTHIM. ANTHIM® (obiltoxaximab) injection, for intravenous use Initial U.S. Approval: 2016 WARNING: HYPERSENSITIVITY and ANAPHYLAXIS See full prescribing information for complete boxed warning. Hypersensitivity reactions, including anaphylaxis, have been reported during ANTHIM infusion (5.1) ANTHIM should be administered in monitored settings by personnel trained and equipped to manage anaphylaxis (1.2, 2.4, 5.1) Stop ANTHIM infusion immediately and treat appropriately if hypersensitivity or anaphylaxis occurs (2.4, 5.1) INDICATIONS AND USAGE ANTHIM® is a monoclonal antibody directed against the protective antigen of Bacillus anthracis. It is indicated in adult and pediatric patients for treatment of inhalational anthrax due to B. anthracis in combination with appropriate antibacterial drugs and, for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate. (1.1) Limitations of Use ANTHIM should only be used for prophylaxis when its benefit for prevention of inhalational anthrax outweighs the risk of hypersensitivity and anaphylaxis. (1.2, 5.1) The effectiveness of ANTHIM is based solely on efficacy studies in animal models of inhalational anthrax. (1.2, 14) There have been no studies of the safety or pharmacokinetics (PK) of ANTHIM in the pediatric population. Dosing in pediatric patients was derived using a population PK approach. (1.2, 8.4) ANTHIM does not have direct antibacterial activity. ANTHIM should be used in combination with appropriate antibacterial drugs. (1.2) ANTHIM is not expected to cross the blood-brain barrier and does not prevent or treat meningitis.
    [Show full text]
  • Proteomics Tech Note 5802
    proteomics tech note 5802 A Practical Approach to Proteomics Sean Taylor, Katrina Academia, Anthony Alburo, Aran Paulus, Kate Smith, and Considering all the possibilities, it is likely that any genome can Tanis Correa, Bio-Rad Laboratories, Inc. 2000 Alfred Nobel Drive, Hercules, CA potentially give rise to an infinite number of proteomes. Because 94547 USA proteins, not genes, are ultimately responsible for the phenotypic Since the completion of the human genome project, changes in cells and tissues, the mechanisms of disease, aging, sequencing technologies have continued to evolve, providing and environmental effects cannot be elucidated solely by tools for the rapid sequencing of most model organism studying the genome. The targets of drugs and chemicals are genomes. Associated genomic and transcriptomic data from proteins, and only through a survey of the proteome can the microarray and real-time PCR technologies have yielded associated mechanisms be understood. Most importantly, the a wealth of new information and deeper understanding of differential expression of mRNA (up or down) can capture at most biological systems. This genomic information has opened 40% of the variation of protein expression (Tian et al. 2004). up the field of proteomics, allowing the identification and The initial goal of most proteomics projects is to identify and comparison of differentially expressed proteins, from bacteria determine differential protein expression between samples. Once to humans. The accumulated data show that changes a list of differentially expressed proteins has been established, the in mRNA levels account for less than half of the relative subsequent step is to perform a detailed analysis of individual expression differences observed between associated proteins.
    [Show full text]
  • Human Cytomegalovirus UL141 Protein Interacts with CELF5 and Affects Viral DNA Replication
    MOLECULAR MEDICINE REPORTS 17: 4657-4664, 2018 Human cytomegalovirus UL141 protein interacts with CELF5 and affects viral DNA replication FEI ZOU1,2*, ZHI-TAO LU3*, SHUANG WANG1, SI WU1, YING-YING WU1 and ZHENG-RONG SUN1 1Department of BioBank, Affiliated Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004; 2Department of Pediatrics, First Hospital of Jilin University, Changchun, Jilin 130021; 3Department of Pediatrics, Zhangjiagang First People's Hospital, Zhangjiagang, Jiangsu 215600, P.R. China Received June 14, 2017; Accepted January 5, 2018 DOI: 10.3892/mmr.2018.8419 Abstract. Human cytomegalovirus (HCMV) infection is the regulation of HCMV genomic DNA synthesis, which is a key primary viral cause of congenital abnormalities and mental step during HCMV infection leading to neurological disease. retardation in newborns. The HCMV UL141-encoded glyco- protein has been previously revealed to inhibit the cell-surface Introduction expression of cluster of differentiation (CD)155, CD122, tumor necrosis factor-related apoptosis-inducing ligand death Human cytomegalovirus (HCMV) is a ubiquitous herpes virus (TRAIL)-receptor 1 (R1) and TRAIL-receptor 2 (R2), thus with infection rate of ~50-80% in females of reproductive age protecting virally-infected cells by allowing them to escape from different regions of the world, including Australia, Canada, natural killer cell-mediated cytotoxicity. The present study United States, Sweden, Finland, Spain, United Kingdom and investigated the interaction between HCMV UL141 and Ghana (1). Following an HCMV infection, the primary clinical human fetal brain cDNA to elucidate the possible effects of manifestations in healthy people are asymptomatic reces- UL141 on the nervous system. The findings of the current sive or latent infections.
    [Show full text]
  • Developing Biodefense Ivds Is Still a Priority John Conroy
    Beyond Clinical Applications Developing biodefense IVDs is still a priority John Conroy In a scary world, nonclinical diagnostic testing spies a few challenges and many opportunities. s anthrax scares go, this one had that false alerts have become a fact of 1 Environmental and biowarfare. The as benign a beginning and ending life for lawmakers and their staffs. "We report noted that new technologies A as possible in today's terror- get a few of these a day," the spokesman have emerged since the 9/11 attacks to obsessed world. A New York City mu- told the Houston Chronicle. improve the detection, prevention, and sician who returned from Africa in As these stories attest, challenges and surveillance of bioterrorist attacks. February with unprocessed animal skins opportunities abound for IVD firms in a These technologies include rapid tests tested positive for anthrax. The 44-year- world where infectious diseases and for smallpox, anthrax, and salmonella, old man bought the skins, which con- bioterrorism agents are just a plane as well as improved vaccines and in- tained anthrax spores, to make tradi- flight, mail drop, cargo dock, or car ride formation-awareness networks to ex- tional African drums, authorities said. away. Market applications include tests pedite tracking the symptoms of chem- Complaining of flu-like symptoms, the for biodefense, avian flu, West Nile ical and biological events. musician collapsed while on tour with virus, food, animals and pets, water qual- his dance troupe in Pennsylvania, where ity, and genetically modified food. Test- • Food microbiology. In 2003, the glob- he was hospitalized. ing formats include ELISA, rapid later- al market for food microbiology tests Notable for their slightly more prosa- al-flow technology, and real-time was an estimated $864 million with an ic origins, similar stories of viral, toxic, polymerase chain reaction (PCR).
    [Show full text]
  • Superscript® III Platinum® SYBR® Green
    Page 4 Troubleshooting Guide Problem Possible Cause Solution ® ® ® No amplification product; cDNA synthesis temperature too Lower incubation temperature. SuperScript III Platinum SYBR Green One-Step qRT-PCR Kit Relative fluorescent high, low priming efficiency Cat. no. 11736-051 Size: 100 reactions signal ≤ background or RT or cDNA primer blocked by Raise incubation temperature. Redesign primer(s). Cat. no. 11736-059 Size: 500 reactions no-template control secondary structure RNA has been damaged/degraded Replace RNA if necessary. Store at -20°C RNase contamination Maintain aseptic conditions; add RNase inhibitor. Description Poor sensitivity Not enough template RNA Increase concentration of template RNA; use 10 ng–1 μg total RNA. The SuperScript® III Platinum® SYBR® Green One-Step qRT-PCR kit a one-step quantitative RT-PCR kit for the detection and Product detected at RNA has been damaged/degraded Replace RNA if necessary. quantification of RNA using real-time detection instruments. This system combines SuperScript® III Reverse Transcriptase higher than expected RNase contamination Maintain aseptic conditions; add RNase inhibitor. ® ® cycle number (RT) and Platinum Taq DNA Polymerase in a single enzyme mix, with SYBR Green I fluorescent dye in a separate 2X RT inhibitors are present in RNA Remove inhibitors in the RNA preparation by an additional 70% reaction mix. Both cDNA synthesis and PCR are performed in a single tube using gene-specific primers and either total RNA ethanol wash. Inhibitors of RT include SDS, EDTA, guanidium or mRNA. Reagents are provided for 100 or 500 amplification reactions of 50 μl each. salts, formamide, sodium phosphate and spermidine. Inefficient cDNA synthesis Adjust cDNA synthesis temperature and/or primer design.
    [Show full text]
  • Pulmonary Delivery of Biological Drugs
    pharmaceutics Review Pulmonary Delivery of Biological Drugs Wanling Liang 1,*, Harry W. Pan 1 , Driton Vllasaliu 2 and Jenny K. W. Lam 1 1 Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong, China; [email protected] (H.W.P.); [email protected] (J.K.W.L.) 2 School of Cancer and Pharmaceutical Sciences, King’s College London, 150 Stamford Street, London SE1 9NH, UK; [email protected] * Correspondence: [email protected]; Tel.: +852-3917-9024 Received: 15 September 2020; Accepted: 20 October 2020; Published: 26 October 2020 Abstract: In the last decade, biological drugs have rapidly proliferated and have now become an important therapeutic modality. This is because of their high potency, high specificity and desirable safety profile. The majority of biological drugs are peptide- and protein-based therapeutics with poor oral bioavailability. They are normally administered by parenteral injection (with a very few exceptions). Pulmonary delivery is an attractive non-invasive alternative route of administration for local and systemic delivery of biologics with immense potential to treat various diseases, including diabetes, cystic fibrosis, respiratory viral infection and asthma, etc. The massive surface area and extensive vascularisation in the lungs enable rapid absorption and fast onset of action. Despite the benefits of pulmonary delivery, development of inhalable biological drug is a challenging task. There are various anatomical, physiological and immunological barriers that affect the therapeutic efficacy of inhaled formulations. This review assesses the characteristics of biological drugs and the barriers to pulmonary drug delivery.
    [Show full text]
  • Union Calendar No. 603
    Union Calendar No. 603 110TH CONGRESS " ! REPORT 2d Session HOUSE OF REPRESENTATIVES 110–930 ACTIVITIES OF THE COMMITTEE ON OVERSIGHT AND GOVERNMENT REFORM ONE HUNDRED TENTH CONGRESS FIRST AND SECOND SESSIONS 2007–2008 Available via the World Wide Web: http://www.gpoaccess.gov/congress/ index.html http://www.house.gov/reform JANUARY 2, 2009.—Committed to the Committee of the Whole House on the State of the Union and ordered to be printed VerDate Aug 31 2005 01:57 Jan 03, 2009 Jkt 046108 PO 00000 Frm 00001 Fmt 6012 Sfmt 6012 E:\HR\OC\HR930.XXX HR930 smartinez on PROD1PC64 with REPORTS congress.#13 ACTIVITIES REPORT OF THE HOUSE COMMITTEE ON OVERSIGHT AND GOVERNMENT REFORM VerDate Aug 31 2005 01:57 Jan 03, 2009 Jkt 046108 PO 00000 Frm 00002 Fmt 6019 Sfmt 6019 E:\HR\OC\HR930.XXX HR930 smartinez on PROD1PC64 with REPORTS with PROD1PC64 on smartinez 1 Union Calendar No. 603 110TH CONGRESS " ! REPORT 2d Session HOUSE OF REPRESENTATIVES 110–930 ACTIVITIES OF THE COMMITTEE ON OVERSIGHT AND GOVERNMENT REFORM ONE HUNDRED TENTH CONGRESS FIRST AND SECOND SESSIONS 2007–2008 Available via the World Wide Web: http://www.gpoaccess.gov/congress/ index.html http://www.house.gov/reform JANUARY 2, 2009.—Committed to the Committee of the Whole House on the State of the Union and ordered to be printed U.S. GOVERNMENT PRINTING OFFICE 46–108 WASHINGTON : 2009 VerDate Aug 31 2005 01:57 Jan 03, 2009 Jkt 046108 PO 00000 Frm 00003 Fmt 4012 Sfmt 4012 E:\HR\OC\HR930.XXX HR930 smartinez on PROD1PC64 with REPORTS congress.#13 COMMITTEE ON OVERSIGHT AND GOVERNMENT REFORM HENRY A.
    [Show full text]
  • CONGRESS SUMMARY REPORT May 13-16, 2014 | Miami, Florida
    CONGRESS SUMMARY REPORT May 13-16, 2014 | Miami, Florida CONVENED BY IN ASSOCIATION WITH CONTENTS Organizing and Program Commitee 1-2 Members 3-4 Overview 2014 Congress 6 Features 2014 Congress 7-8 Statistics Student 9 Reflections Value of 10 ISCMR Partnership 2014 Congress 11 Fact Sheet Plenary 12-26 Sessions Sponsors 29 & Exhibitors All quotations in this summary have been taken from the congress evaluations completed by the attendees. The New Investigator’s Luncheon was one of the most exciting experiences that a trainee could have had, especially for those just starting their careers in this life-long journey of research. The advice of world-renown leading senior researchers was truly helpful and will be remembered in times of hardships that may come in the future. Thank you!!! Organizing Committee Adi Haramati, PhD Mary Jo Kreitzer, PhD, RN Organizing Committee, Co-Chair Fundraising Committee, Co-Chair Georgetown University School of University of Minnesota, USA Medicine, USA Robert Saper, MD, MPH Adam Perlman, MD, MPH Organizing Committee, Co-Chair Fundraising Committee, Co-Chair Boston University School of Medicine, USA Duke University, USA Judith Balk, MD, MPH, FACOG Choi Seung-hoon, PhD, KMD Communications Committee Chair 2015 ICCMR Site Host Temple University School of Medicine, Korea Institute of Oriental Medicine, Korea West Penn Allegheny Health System, USA Margaret Chesney, PhD Samantha Simmons, MPH Vice Chair, Consortium of Academic Local Site Committee, Chair Health Centers, USA Oregon Health Sciences University, USA David
    [Show full text]
  • 125509Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 125509Orig1s000 ADMINISTRATIVE and CORRESPONDENCE DOCUMENTS ACTION PACKAGE CHECKLIST APPLICATION INFORMATION1 If NDA, Efficacy Supplement Type: BLA #125509 BLA Supplement # (an action package is not required for SE8 or SE9 supplements) Proprietary Name: Anthim Applicant: Elusys Therapeutics, Inc. Established/Proper Name: obiltoxaximab Agent for Applicant (if applicable): Dosage Form: injection RPM: Jane A. Dean, RN, MSN Division: Division of Anti-Infective Products For ALL 505(b)(2) applications, two months prior to EVERY action: NDA Application Type: 505(b)(1) 505(b)(2) Efficacy Supplement: 505(b)(1) 505(b)(2) Review the information in the 505(b)(2) Assessment and submit the draft2 to CDER OND IO for clearance. BLA Application Type: 351(k) 351(a) Check Orange Book for newly listed patents and/or Efficacy Supplement: 351(k) 351(a) exclusivity (including pediatric exclusivity) No changes New patent/exclusivity (notify CDER OND IO) Date of check: Note: If pediatric exclusivity has been granted or the pediatric information in the labeling of the listed drug changed, determine whether pediatric information needs to be added to or deleted from the labeling of this drug. Actions Proposed action AP TA CR User Fee Goal Date is 3/20/16 Previous actions (specify type and date for each action taken) None If accelerated approval or approval based on efficacy studies in animals, were promotional materials received? Note: Promotional materials to be used within 120 days after approval must have been Received submitted (for exceptions, see http://www fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guida nces/ucm069965.pdf).
    [Show full text]